All Rifampicin articles
-
NewsNanoparticles with antibacterial action shorten duration of tuberculosis treatment
A low-cost technology involving nanoparticles loaded with antibiotics and other antimicrobial compounds that can be used in multiple attacks on infections by the bacterium responsible for most cases of tuberculosis has been developed.
-
NewsNIH clinical trial of tuberculous meningitis drug regimen begins
A trial of a new drug regimen to treat tuberculous meningitis (TBM) has started enrolling adults and adolescents in several countries where tuberculosis (TB) is prevalent.
-
NewsDrug-resistant tuberculosis may be under-diagnosed, reveals genomic analysis
This genomic sequencing study, in southern Mozambique, is the first to characterise the drug resistance profile at the population level and identify mutations that escape routine diagnostic tests.
-
NewsNewly engineered versions of bacterial enzyme reveal how antibiotics could be more potent
Researchers have generated the full inventory of mutations in the bacterial species Escherichia coli where the antibiotic rifampicin attaches to and disables an essential bacterial enzyme known as RNA polymerase (RNAP).
